NASDAQ
6.29USD
+0.04 (+0.64%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
260.4M
P/E
—
EPS
—
Beta
1.15
52W range
4.48-13.22
Day range
6.02–6.38
Open
6.17
Prev close
6.25
Volume
894.4K
Avg volume
1.1M
Dividend
0.00
IPO
2021-07-30
https://www.marketbeat.com/instant-alerts/rxsight-q2-earnings-call-highlights-2026-08-06/ · 8/6/2026-0.60
https://www.globenewswire.com/news-release/2026/07/26/3333226/0/en/RxSight-Reports-Inducement-Grants-as-Permitted-by-the-Nasdaq-Listing-Rules.html · 7/26/2026+0.20
https://www.zacks.com/stock/news/2955281/rxsight-rxst-surges-6-1-is-this-an-indication-of-further-gains?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2955281 · 7/17/2026+0.60
https://www.marketbeat.com/instant-alerts/rxsight-q2-sales-sink-20-as-alcon-deal-bolsters-2026-outlook-2026-07-10/ · 7/11/2026-0.20
https://www.benzinga.com/trading-ideas/long-ideas/26/07/60296842/rivian-automotive-penguin-solutions-and-3-stocks-to-watch-heading-into-tuesday · 7/7/2026-0.10
https://www.barrons.com/articles/rackspace-amd-ai-data-centers-aebdbae1 · 6/16/2026+0.60
https://www.globenewswire.com/news-release/2026/01/20/3222286/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-RxSight-Inc-RXST.html · 1/20/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-rxsight-inc---rxst-302654853.html · 1/8/2026-1.00
https://seekingalpha.com/article/4824774-rxsight-stock-potential-sharp-short-term-rebound · 9/22/2025+0.80
https://www.prnewswire.com/news-releases/rxst-investors-have-opportunity-to-lead-rxsight-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302562499.html · 9/22/2025-1.00
https://www.prnewswire.com/news-releases/investor-alert-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-rxsight-302560919.html · 9/18/2025-1.00
https://www.globenewswire.com/news-release/2025/09/18/3152134/683/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-RxSight.html · 9/18/2025-1.00
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
